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Abstract
Sterilising immunity is a desired outcome for vaccination against human immunodeficiency virus (HIV) and has been
observed in the macaque model using inactivated simian immunodeficiency virus (SIV). This protection was attributed to
antibodies specific for cell proteins including human leucocyte antigens (HLA) class I and II incorporated into virions during
vaccine and challenge virus preparation. We show here, using HLA bead arrays, that vaccinated macaques protected from
virus challenge had higher serum antibody reactivity compared with non-protected animals. Moreover, reactivity was
shown to be directed against HLA framework determinants. Previous studies failed to correlate serum antibody mediated
virus neutralisation with protection and were confounded by cytotoxic effects. Using a virus entry assay based on TZM-bl
cells we now report that, in the presence of complement, serum antibody titres that neutralise virus infectivity were higher
in protected animals. We propose that complement-augmented virus neutralisation is a key factor in inducing sterilising
immunity and may be difficult to achieve with HIV/SIV Env-based vaccines. Understanding how to overcome the apparent
block of inactivated SIV vaccines to elicit anti-envelope protein antibodies that effectively engage the complement system
could enable novel anti-HIV antibody vaccines that induce potent, virolytic serological response to be developed.
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Introduction
The ability to induce virus-neutralising antibodies is considered
a key property for an efficacious HIV/AIDS vaccine [1,2]. This
will be particularly critical for protection against infection with
HIV as, once the virus gains access to the lymphoid system; it
spreads rapidly and establishes pockets of latency through the
integration of proviral DNA. Thus, unlike for most existing
vaccines, for HIV it may be necessary to establish sterilising
immunity. However, the properties of antibodies induced by
vaccination that can confer potent protection remain poorly
defined. Anti-envelope antibodies appear to neutralise primarily
through the blocking of interaction of the viral envelope protein
with its receptor CD4 [3].
In animal models, such antibodies have been demonstrated to
protect against infection, but they require high titres or very high
affinity to be effective, which can be difficult to attain in all vaccine
recipients [4–8]. In clinical vaccine research, whilst anti envelope
protein antibodies are currently perceived to be a desired
outcome; most emphasis is being placed on characterising the
specificity of antibodies that are able to bind a broadly divergent
range of HIV-1 envelope proteins with high affinity [9,10]. These
antibodies have been derived from infected individuals, who
remain unable to clear the virus. By contrast only limited effort is
being focussed on characterising the functional properties of
antibodies that have been demonstrated to protect solidly against
virus challenge.
Other experimental AIDS vaccines have also been shown to
mediate protection in an antibody dependent manner. Early
studies in simian models used fixed inactivated virus vaccines,
where solid protection against wild-type virus challenge was
reported by a number of groups [11–16]. This vaccine-mediated
protection was shown to be transferable with immune serum alone
[14]. Critically, however, it became apparent that the key vaccine
components were not viral-encoded antigens, but host cell proteins
that were present in the vaccine preparations derived from the
human cellular substrates used [17–20]. Moreover, it was
demonstrated that immunization with HLA class I [21] or HLA
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class II [22] protected a proportion of macaques against challenge
with human cell-grown SIV. However, there were limited analyses
of the mechanism of virus neutralisation, since the antibodies were
induced by xeno-immunisation and were unable to protect
macaques against virus propagated on simian cells [23–25].
Nonetheless, these results highlight the potential of anti-virion
antibodies to mediate protection against virus infection in vivo. By
understanding more fully the mechanisms by which antibodies
directed against host cell proteins on the virion can confer
sterilising protection, it may be possible to design potent, novel,
clinically acceptable anti-HIV vaccines.
For such a mechanism to operate in humans, allo-immunisation
must be effective against HIV. Some studies suggest that this is
possible where alloimmunisation of women with their partner’s
cells induced HIV resistance in vitro [26] and the sera neutralised
HIV when grown in their partner’s white blood cells [27]. Further,
sera from polytransfused patients generating allo-antibodies
(including HLA antibodies) were able to neutralise HIV grown
in cells expressing corresponding HLA [28]. Our own studies have
also shown that immunisation with a fixed inactivated HIV
vaccine produces anti HLA antibody responses that are concor-
dant with the host cell line used to produce the vaccine [29].
The failure of current vaccine strategies to elicit antibodies that
protect with the potency of those induced by fixed inactivated
viruses, led us to apply techniques that were unavailable at the
time of the original vaccine studies, to analyse the properties of
protective sera elicited by fixed inactivated SIV vaccines further.
Here we report that protection with fixed inactivated vaccines
correlates with the presence of antibodies directed against
framework determinants on MHC Class I and II molecules and
also with antibodies that neutralise virus through host cell
components in the presence of complement. By contrast,
neutralisation by anti SIV envelope protein antibodies generated
by the same vaccines did not demonstrate any capacity to harness
complement. These data identify a strategy to develop more
potent vaccines through their ability to elicit anti-HIV antibody
responses that are able to effectively engage complement.
Materials and Methods
Animals
Juvenile, purpose bred, cynomolgus macaques (Macaca fasci-
cularis) were used in strict accordance with UK Home Office
guidelines. Work at NIBSC is governed by the Animals (Scientific
Procedures) Act 1986 which complies with the EC Directive 86/
609 and performed under licence PPL 80/1952 granted only after
review of all the procedures in the licence by the NIBSC Animal
Welfare and Ethical Review Body. All study macaques were
purpose bred in the UK and group-housed for the entire duration
of the study. Macaques are fed primarily with a formulated
pelleted diet, sourced from a specialist UK diet manufacturer. This
diet is intended to be nutritionally complete and balanced for Old
World Primates, but is also supplemented with additional food
items, including a range of fresh fruit and vegetables to give
variety. Food is presented in measured amounts at varying time
points during the day, using a variety of presentation methods to
encourage foraging behaviours. Food intake is monitored and
animals are weighed regularly to check for instances of over -or
under-consumption.
All animals were sedated with ketamine prior to bleeding or
virus inoculation by venepuncture. Frequent checks were made by
staff and any unexpected change in behaviour by individuals on
study followed up, including seeking of veterinary advice where
necessary. Regular blood samples were obtained to assess
haematological parameters in blood that might provide evidence
of incipient disease and veterinary advice sought when persisting
abnormalities detected. The study was terminated and all animals
killed humanely by administering an overdose of pentobarbital
(200 mg/ml) by intra-cardiac puncture. All efforts were made to
minimise animal suffering.
Vaccines
Formalin-inactivated SIVmac25132H was prepared as described
previously [30]. The vaccine was formulated in RIBI as adjuvant
and administered at 500 mg or 100 mg doses. This work was
performed as part of a European wide study [31].
A fixed uninfected C8166 cell based vaccine was prepared as
described previously [32]. Briefly 26106 cells were fixed in 0.15%
glutaraldehyde and 0.2% b-propiolactone and formulated with
100 mg of Quil A or GMDP as adjuvants. A fixed SIVmac25132H
infected C8166 cell based vaccine was prepared and administered
as described previously [16].
All vaccines were administered sub-cutaneously in the quadri-
ceps muscles.
Serology
Sera used in these studies were stored frozen at220uC since the
time of the vaccine studies carried out from 1990 and later.
HLA Bead Array Assay
For analysis of the antibody specificity, a Lifematch Lifecodes
class I and class II ID (Tepnel Life Sciences) kit consisting of beads
coated with pools of either MHC class I or MHC class II glyco-
proteins was used. Serum samples were incubated with the beads
following manufacturer’s instructions and analysed on a LuminexH
machine [29].
Virus Infectivity Neutralisation Assay
Neutralising antibody activity was determined using TZM-bl
cells and an adaptation of the method of Wei et al., (2002) [33].
The test serum which had been incubated at 56uC for 1 hour was
serially diluted in 2 fold steps in DMEM containing 10% v/v foetal
calf serum (FCS) in 96 well microtitre plates. This was performed
in triplicate. Fifty ml of virus stock containing twice the fifty percent
culture infectious dose (TCID50) for each virus (predetermined on
TZM-bl cells) was added to all wells and the antibody/virus
mixture incubated for 45 minutes. 20 ml of normal macaque
serum which had not been heat treated was added as a source of
autologous complement and the mixture incubated for a further
15 minutes. Replicate plates were set up with heat-treated (56uC
for 1 hour) normal macaque serum to control for complement
activity. The indicator cell line TZM-bl which expresses b-
galactosidase and luciferase on infection with HIV or SIV was
added to the wells (10,000 cells per well) and the plate incubated at
37uC for 48 hours.
Following incubation, the supernatant was removed by aspira-
tion and the cells lysed by the addition of lysis buffer containing
5% NP40. The presence of b galactosidase in the cell lysate was
determined using a Novagen b-red b-galactosidase kit (Novagen
Inc.) and following the manufacturer’s instructions. The colour
development was terminated using the kit stop solution and the
absorbance at 590 nm determined using a Fluostar Omega
microplate spectrophotometer (BMG Labtech, Ortenburg, Ger-
many).
Anti-class I and II monoclonal antibodies were included in some
assays to confirm HLA specific neutralization. W6/32(class I) and
HLA Antibody Association with SIV Protection
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HL-39 (class II) mabs were used and derived from AbD Serotec,
Oxford, UK.
Viruses and Cells
The following viruses were used in neutralisation assays;
SHIVW61D [34] SIVsme660 [35]. These viruses were propagated
either on the human CD4+ human lymphoblastoid cell line
C8166; C8166 cells are a subclone of CR63/CR-4 cells derived by
cell hybridization, and transformed in vitro by co-cultivation with
HTLV-I producing cells [36]. Alternatively, viruses were propa-
gated on HSC-F cells, a cynomolgus monkey CD4+ T-cell line
from a foetal splenocyte that was immortalized by infection with
Herpesvirus saimiri subtype C [37].
Virus Detection ex vivo
Virus isolation from peripheral blood mononuclear cells
(PBMC) was determined by co-culture with C8166 cells [38];
the presence of replicating virus was confirmed by visual
identification of syncitia and SIVGagp24 antigen capture assay
[39]. The presence of SIV in DNA isolated from whole blood was
determined using SIVgag DNA PCR assay [39].
Experimental Outline
The vaccine studies using inactivated SIV or uninfected cell
vaccines are summarised in Figures 1, 2, 3. Two groups of 4
macaques (Groups A and B) were administered high (500 mg) or
low (100 mg) doses of inactivated SIVmac25132H formulated in
RIBI adjuvant (Figure 1). Group A received 3 immunisations on
weeks 0, 4 and 8. Group B received 4 immunisations on weeks 0,
4, 8 and 16. This was performed as part of a European multicentre
SIV vaccine study which has been reported previously [31].
Another 4 separate study groups (C-F) of 4 macaques each were
also undertaken. Group C were immunised on two occasions at
weeks 0 and 4 with 26106 fixed, inactivated C8166 cells infected
with SIVmac25132H (Figure 2). Group D were immunised as for
group C except uninfected cells were used (Figure 2). Group E
were immunised as for group C except 4 immunisations were
administered instead of two at weeks 0, 4, 8 and 16 (Figure 3).
Group F were immunised as for group D except that GMDP was
used as adjuvant (Figure 3).
Macaques were challenged intravenously two weeks after the
last dose of vaccine with 10MID50 of the 11/88 pool of
SIVmac25132H [30]. Groups of 4 naı¨ve macaques were
challenged contemporaneously as controls. The outcome of
challenge was monitored by collection of blood samples at weeks
2, 4, 8 and 12 weeks after challenge and looking for evidence of
virus by co-culture with indicator cells and diagnostic SIV specific
DNA PCR [39].
Results
Outcome of Challenge with SIVmac25132H
All animals were virus negative by both co-culture for virus
growth and PCR for gag prior to challenge (Figures 1, 2, 3).
Following intravenous challenge with SIVmac25132H, all naive
challenge controls (n = 16) became infected, detectable by both re-
isolation of virus from PBMC by co-culture and by SIV-specific
DNA PCR at multiple timepoints. Following challenge with
SIVmac25132H, virus was not detected at any time-point in the
blood of any macaques in group A (J134–J137 (Figure 1). In group
B, virus was not detected in the blood at any time of individuals
J138, J140 and J141. However for macaque J139, virus was
detected at weeks 2 and 8 (Figure 1). Following challenge of
macaques in Group C (J68–J70), there was no evidence of SIV in
J68, J70 and J71. Virus was detected in J69 at 2 weeks after
challenge (Figure 2). Amongst the macaques vaccinated with
uninfected C8166 cell based vaccines, there was no evidence of
virus detected in the blood of J72 and J73 in group D (Figure 2),
K147–K149 in group E and N56–N59 in group F (Figure 3). For
the other macaques immunised with uninfected C8166 cells virus
was detected in the blood at multiple times following challenge by
both virus isolation and PCR methods. These animals were as
follows: J74 and J75 (group D; Figure 2), K150 (group E; Figure 3).
Immune Response after Vaccination with Inactivated SIV
or SIV-infected C8166 Cells
Anti-HLA response. Analysis of the specificity of anti-HLA
responses was performed using LuminexH technology and bead
sets covering a range of Class I and Class II alleles.
The anti-HLA response was characterised by a broad reactivity
to all bead sets of both HLA class I and class II (Figures 1, 2, 3). A
dose response was also observed where the median fluorescence
intensities were slightly higher for group A receiving 500 mg SIV
dose than group B vaccinated with100mg dose (not shown).
Although the individual responses were variable in intensity, the
lowest responders were observed to be J139 (group B; Figure 1)
and J70 (group C; Figure 2) for both class I and class II; these were
the macaques that became infected when challenged with virus.
Virus infectivity neutralising antibody. Heat inactivated
sera, collected on the day of virus challenge from macaques that
had been vaccinated with fixed inactivated SIV (Groups A and B -
J134–J141), were evaluated for the ability to neutralise SHIVW61D
propagated on C8166 cells. Neutralising activity, that could be
titrated, was detectable against this virus in all of the sera collected
on the day of challenge (Figure 1) whereas pre-immune sera
showed no activity. When fresh macaque serum was included in
neutralisation assays as a source of complement, the neutralising
titres increased. However the titres in serum from animals that
became infected after challenge (J139; group B and J70; group C)
were readily distinguishable from their contemporaries (figure 1).
This difference was significant (r= 0.034; Mann Whitney U-test).
The addition of complement to the neutralisation assay also
resolved differences in the titres detected in the different vaccine
groups; serum from groups A and B (vaccinated with inactivated
SIV) exhibited more potent neutralisation at low serum dilutions
compared with group C that was vaccinated with SIV infected
C8166 cells. HLA specific neutralising activity was confirmed with
anti-class I and class II monoclonal antibodies W6/32 and HL-39
respectively (data not shown).
Immune Response after Vaccination with Uninfected
C8166 Cells
Anti-HLA response. Following vaccination uninfected
C8166 cells, similar anti–HLA Class I and II responses were
detected as those observed following immunisation with inactivat-
ed SIV (Figs. 4, 5, 6). Broad reactivity to all class I and II bead sets
was observed. However, the vaccinated macaques which became
patently infected after SIV challenge (J75, group D and K150,
group E) had the lowest median fluorescence intensity within their
vaccine groups.
Virus infectivity neutralising antibody. A similar profile
of complement mediated neutralising activity was observed
amongst macaques immunised with uninfected C8166 cells to
those immunised with inactivated SIV vaccines (fig. 5). In the
absence of complement, there was neutralising activity (,60%
viral growth) in some animals of all the vaccine groups except
animals K148, K149 and K150 (group E) and J73 (group D). With
HLA Antibody Association with SIV Protection
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complement, neutralising activity at ,60% viral growth was
achieved in all sera except those from the unprotected animals (J75
and K150; serum for J74 was not available for analysis) (Fig. 5).
This difference did not quite reach significance at the 5% level
(r= 0.059; Mann Whitney U test).
Serum neutralising activity was tested against a different virus
strain (SIVsmE660) that had been propagated on C8166 cells. No
neutralising activity was detected in the sera of macaques from
group D (K147, K148 and K150; figure 6), in the absence of
complement. However, when complement was added, serum
neutralising activity against this second virus was detectable in all
sera except from macaque K150 that was not protected when
challenged with SIVmac25132H. For this individual, sera collected
after immunisation exhibited neutralising titres similar to pre-
immune sera.
Effect of Cell Substrate on Complement-mediated Virus
Infectivity Neutralising Activity
In previously reported studies [40], protection was observed in
immunised macaques only when they were challenged with SIV
that had been propagated on the same human cell lines as those
used to prepare the vaccines. By contrast, no protection was
observed when macaques were challenged with viruses derived
from macaque cells [20]. We sought to investigate whether the
complement dependent neutralising activity detectable in the
serum of macaques after immunisation with fixed inactivated
vaccines was similarly dependent upon whether the virus had been
propagated on human or macaques cells. SHIVW61D stocks were
prepared by passage of the virus stocks used in the assays described
above on the macaque-derived cell line, HSC-F [37]. Heat
inactivated sera collected from macaques immunised with either
inactivated SIV (J69; group C) or uninfected C8166 cells (J73;
group D) vaccines exhibited detectable neutralisation of
SHIVW61D propagated on the concordant C8166 cell, but no
Figure 1. Association between anti-HLA reactivity following vaccination with formalin-inactivated SIV and outcome of challenge.
Virus infection status was determined by PCR for SIVgag proviral DNA and virus isolation (VI) from PBMC of macaques challenged with SIVmac25132H
(a) following vaccination with inactivated SIV with either 36500 mg doses (group A) or 46100 mg doses (group B). Bar charts show the associated
median fluorescence intensity (y axis) of serum samples for each macaque tested against HLA class I (red bars) and class II (green bars) bead sets (x
axis). Background binding of pre-vaccination sera is shown as light red and light green for HLA class I and class II respectively. * indicates not tested,
probe number refers HLA allele-specific bead sets.
doi:10.1371/journal.pone.0088735.g001
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activity was observed when the same virus was propagated on the
simian HSC-F cell line (Figure 7).
Discussion
The development of vaccines that are able to generate potent
anti-viral antibody responses against a broad range HIV-1
strains, would be a major breakthrough. Several years ago, it
was demonstrated that inactivated viral vaccines prepared using
a number of different approaches were able to protect
macaques against detectable infection with SIV, even when
challenged by the intravenous route [14,15,31]. Furthermore,
this vaccine protection could be transferred with serum alone
[14], indicating strongly that the vaccine protection was
antibody mediated. However, in these studies vaccine efficacy
was attributed to an immune response against cellular antigens
(chiefly HLA proteins) incorporated into SIV during the
budding process and which are common between both the
vaccine and challenge virus [17]. The crucial evidence for this
was that immunisation with uninfected cells identical with those
used to propagate the challenge virus could also elicit a
protective response [20]. However, in none of these preceding
studies, was it elucidated why the potent protection conferred
with anti-cell antibodies had not been recapitulated with anti-
virus envelope protein antibodies. In this study, we sought to
apply serological assays not available at the time of the original
vaccine studies, to dissect the anti-viral properties of sera from
macaques that had received inactivated vaccines and been
challenged with virus. Analysis of sera from vaccinated
macaques, within groups where only a proportion of vaccinates
were protected, has identified assays able to establish correla-
tions between specific serological responses and vaccine protec-
tion. These conclusions inform us of the properties of antibodies
that an AIDS vaccine needs to elicit to deliver potent anti-HIV
protection.
At the time when fixed inactivated vaccine studies were
performed, it was hypothesised that a likely candidate respon-
sible for inducing protective immunity in these macaque studies
Figure 2. Association between anti-HLA reactivity following vaccination with fixed-inactivated SIV infected and uninfected C8166
cells and outcome of challenge. Virus infection status was determined by PCR for SIVgag proviral DNA and virus isolation (VI) from PBMC of
macaques challenged with SIVmac25132H (a) following vaccination with 2 doses of SIV infected C8166 cells (group C) or with uninfected C8166 cells
(group D). Bar charts show the associated median fluorescence intensity (y axis) of serum samples for each macaque tested against HLA class I (red
bars) and class II (green bars) bead sets (x axis). Background binding of pre-vaccination sera is shown as light red and light green for HLA class I and
class II respectively. * indicates not tested, probe number refers HLA allele-specific bead sets.
doi:10.1371/journal.pone.0088735.g002
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was human leucocyte antigens (HLA) as these comprise a
significant proportion of the viral proteome [17]. Studies using
HLA class I and II based vaccines were conducted [21,22,40]
and protection was observed which supported this hypothesis. In
this study, we have re-examined the sera from those original
vaccine studies in more detail, using new methodologies. These
new data identified that the magnitude of the anti-HLA
antibody response elicited, by immunisation with fixed inacti-
vated SIV and measured using a LuminexH based assay,
discriminated between protected and infected macaques. The
association between the magnitude of the response determined
by the HLA bead-array assay and protection was most telling
within vaccine groups where only a proportion of immunised
individuals were protected. In all cases, both the anti-HLA Class
I and anti-HLA Class II responses were lowest in those
members of the group that became infected upon virus
challenge.
By using a panel of LuminexH beads expressing different HLA
allotypes, it was shown that the anti HLA responses in the immune
sera was directed against framework determinants, since there was
equal reactivity to multiple antigen bead sets. These data contrast
with those we have reported previously, when we dissected the
specificity of anti HLA class I and class II responses in HIV
infected individuals administered a fixed inactivated HIV im-
muno-therapeutic ‘‘Remune’’. In that report, responses in sera
were directed against specific HLA alleles, suggesting that the
responses were allotypic. Furthermore the responses following
treatment with Remune did not break tolerance [29]. This
distinction in the epitope specificity of anti HLA antibodies should
be considered when extrapolating from xeno-immunisation studies
in macaques to allo-immunisation in man and its potential as an
AIDS vaccine.
The second assay that-was applied to analyse sera, was the
neutralisation of virus infectivity using the TZM-bl cell line [33]
as the target cell. Earlier neutralisation assays used permissive T
Figure 3. Association between anti-HLA reactivity following vaccination with uninfected C8166 cells using different adjuvants and
outcome of challenge. Virus infection status was determined by PCR for SIVgag proviral DNA and virus isolation (VI) from PBMC of macaques
challenged with SIVmac25132H (a) following vaccination with 4 doses of uninfected C8166 cells with Quil A adjuvant (group E) or with GMDP adjuvant
(group F) (a) following vaccination with 2 doses of SIV infected C8166 cells (group C) or with uninfected C8166 cells (group D). Bar charts show the
associated median fluorescence intensity (y axis) of serum samples for each macaque tested against HLA class I (red bars) and class II (green bars)
bead sets (x axis). Background binding of pre-vaccination sera is shown as light red and light green for HLA class I and class II respectively. * indicates
not tested, probe number refers HLA allele-specific bead sets.
doi:10.1371/journal.pone.0088735.g003
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cell lines such as C8166 and required assays to run for several
weeks. As a result, the assays yielded confounding data arising
from the cytotoxic effects of anti-HLA antibodies during long
term cultures. The TZM-bl based assay measures virus infection
(not virus replication), and so the assays are not protracted and
cytoxicity is minimised. Using the infectivity assays, virus
neutralisation was examined in the presence and absence of
normal macaque serum, as a source of complement. In addition
to the cells, different virus stocks were used to dissect the
specificity of the virus neutralising activity. Stocks of both SIV
and SIV/HIV-1 envelope chimera (SHIVW61D) [34] were used
that had been prepared on either the human T cell line C8166
[36] or the simian T cell line HSC-F [37]. With these assays,
we were able to discriminate between complement dependent
and independent neutralisation targeted at viral and host cell
proteins. Since both SIV and SHIV stocks were neutralised in a
complement dependent manner when passaged on human T
cells line and there are no reports of cross reactivity between
HIV-1 and SIV envelope proteins, we conclude that vaccine
protection correlated with complement mediated neutralisation
of the virion by antibodies that were primarily specific for
human host cell antigens. This was the case irrespective of
whether inactivated virus, virus infected cells or inactivated
uninfected cells were used as the vaccine. Thus, we conclude
that this neutralising activity is directed against non SIV
proteins such as the anti-HLA response detected with the
LuminexH based assay.
The critical feature required to demonstrate a correlation
between the virus neutralising antibody activity and protection
against virus challenge was the titre of neutralising antibodies
detected in the presence of complement. Although virus
neutralisation was detectable in many serum samples in the
absence of complement, the ability to differentiate protected
from unprotected animals was not apparent until complement
was added (Figures 4 and 5). Our data obtained in assays,
performed without added complement, mirror those obtained
by others who have been unable to detect a correlation between
complement independent virus neutralisation and protection
following immunisation with inactivated SIV vaccine, using a
variety of assay formats [41]. Furthermore, others have reported
previously that anti-cell antibodies, elicited by fixed inactivated
SIV vaccines, are able to mediate virolysis in the presence of
complement [21,45]. Nevertheless, the data presented in this
study are the first to demonstrate that the titre of these
complement mediated neutralising antibodies correlate with the
vaccine mediated protection against infection. This is due to our
access to sera from vaccine studies where only a proportion of
vaccinated individuals were protected and the application of a
vaccine infectivity based virus neutralisation assay.
Figure 4. Virus infectivity neutralising activity following vaccination with inactivated SIV. Neutralising antibody activity against SHIVW61D
propagated on human C8166 cells in sera from macaques immunised with SIV-containing vaccines in the absence (left panel) or presence (right
panel) of complement. Pre-immune sera (black line) are means of all animals with standard deviations. Group A immunised with 500 mg of
inactivated SIV (red lines); group B immunised with 100 mg of inactivated SIV (blue lines) group C immunised with SIV-infected C8166 cells (green
lines). Dashed lines indicate unprotected animals.
doi:10.1371/journal.pone.0088735.g004
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Whilst the titres of complement mediated neutralising
antibody protection correlated with protection, they were not
remarkably high. This is consistent with the reports of Spear
et al. [42] and Montefiori et al [45], that reported virolysis was
detectable in serum at dilutions between 1/30 and 1/300.
Nevertheless even with these apparently moderate serological
titres, potent reductions in virus titres were demonstrable in vitro
[45]. This might suggest that only moderate titres of antibody
are required when anti-viral antibodies are able to effectively
engage complement. Previously it has been demonstrated that
neutralising activity that engages complement induces virolysis
[43]. Whether this is the only mechanism which applies in vivo is
not known. The key advantage arising from the activation of
complement is that it enables antibodies that are not of the
highest affinity and in relatively low concentration to inactivate
incoming virions. Theoretically, by engaging the complement
system, one antibody molecule may lyse many virions.
If the correlation between vaccine mediated protection and
the titre of anti-virion antibodies capable of engaging comple-
ment-mediated neutralisation proves indeed to be the mecha-
nism, then there are a number of implications. No evidence of
complement mediated neutralisation was detected in immune
sera when they were tested against SIV propagated on the
macaque cell line HSC-F. Similar data have been obtained
previously by others [21,45]. Thus, in vivo protection mediated
in this manner must be extremely potent as it must be achieved
by the neutralisation of every virion in the infectious inoculum,
since all progeny virus will no longer express human cellular
antigens. This is remarkable since sterilising immunity was
reported by a number of groups [11,12,23]. At the same time,
these data highlight a challenge for HIV vaccine design. Whilst
fixed inactivated vaccines are able to elicit anti-cell antibodies
that are able to engage complement to neutralise virus, the
same vaccines appear completely unable to elicit anti-virus
envelope antibodies with the same functional properties. The
reasons for this are unclear. Although complement mediated
antibody neutralisation has been described against HIV it has
only been reported in sera from infected individuals [44–46]
and not in vaccinated subjects. This may highlight important
differences between the immunogenicity of natural virus
infection and HIV-1 vaccines, which have yet to be explained.
One possibility is that envelope spike density is too low and
precludes bivalent binding by neutralising antibody [47–49]
necessary for complement binding. A more intriguing possibility
is that the remote topography of the neutralising antibody
epitopes on the trimer spike or the high level of glycosylation is
not compatible with efficient engagement and delivery of the
complement membrane attack complex on to the virion
membrane. The latter is supported by the report of Jiang et al
[50].
Hessell at al [51] showed that engineering out the comple-
ment binding activity of an anti- HIV-1 envelope antibody did
Figure 5. Virus infectivity neutralising activity following vaccination with uninfected cells. Neutralising antibody activity against
SHIVW61D propagated on human C8166 cells in sera from macaques immunised with uninfected C8166 cell vaccines in the absence (left panel) or
presence (right panel) of complement. Pre-immune sera (black line) are means of all animals with standard deviations. Group D (pink lines); group E
(purple lines) group F (pale brown lines). Dashed lines indicate unprotected animals.
doi:10.1371/journal.pone.0088735.g005
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not impact on the protection observed when it was passively
administered to macaques prior to SHIV challenge. This
observation supports our view that anti-SIV gp140 envelope
antibodies do not engage complement effectively and are unable
to cause complement mediated virolysis. Thus the neutralisation
activity of envelope specific antibodies function through receptor
blockade mechanisms which requires both high titre and high
affinity antibodies to achieve sterilising immunity in vivo [52]. By
contrast, anti-host cell antibodies generated by fixed inactivated
virus vaccines appear more readily able to engage the
complement system. Particularly potent antibodies are those
directed against HLA Class I and II antigens, whether they are
generated in macaques by vaccination [13–15,22] or derived
from the serum of poly-transfused humans [44]. Attempts to
recapitulate this sero-reactivity by allo-immunisation would
appear more difficult [53]. Of course the specificity of anti-
HLA antibodies generated by fixed inactivated vaccines in an
allo situation are distinct [25] compared with the data presented
in this paper (Fig. 1 and 2). In addition, antibody responses to
further host cell antigens may contribute to the protection in a
xeno-immunisation setting that would not be present in an allo-
immune response. Of particular interest are responses to the
complement regulatory proteins CD46, CD55 and CD59 [45].
The detection of these proteins on virions may account for the
inability of complement to mediate virolysis, unless the blocking
antibodies generated by xeno-immunisation are present. How-
ever, more recent data by Morner et al [54]have shown that
macaques immunised with purified recombinant MHC Class I
and II are also able to generate virus neutralising antibodies
that exhibit enhanced titres when complement is present in the
assay. Thus the anti-complement regulatory protein response is
unlikely to be critical.
Engaging the complement system with anti-HIV antibodies
needs to be undertaken with caution. Detailed analysis of infection
sera from individuals has identified that prior to the appearance of
serological responses that neutralise in vitro, non-neutralising
antibodies can enhance virus uptake and infection of cells by
engaging complement [55,56]. This is of concern and a detailed
understanding of the early antibodies that facilitate virus uptake in
these in vitro assays is required. However, in a vaccine scenario, it is
envisaged that the immune response will have matured further
beyond this period of increased susceptibility before individuals
encounter the virus.
The retrospective analysis of the protective serological
responses generated by fixed inactivated virus vaccines informs
the current interest in antibody mediated protection contribut-
ing to an effective AIDS vaccine. At the moment, most
emphasis is focused on identifying how to generate high affinity,
broadly cross reactive binding antibodies that block gp120/CD4
binding [10] and the analysis of required Ig V region sequences
suggest that highly complex immunogens and immunisation
regimens are likely to be required to elicit these responses [9].
We believe that these new data identifying an in vitro correlate
of complement-mediated virus neutralisation with serum-medi-
Figure 6. Infectivity neutralising activity against virus unrelated to vaccine. Neutralising antibody activity against SIVsmE660 propagated
on human C8166 cells in sera from macaques immunised with uninfected C8166 cell vaccines (group E) in the absence (left panel) or presence (right
panel) of complement. Pre-immune sera (black line) shows means of all animals with standard deviations. Dashed lines indicate unprotected animal.
doi:10.1371/journal.pone.0088735.g006
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ated protection in the SIV/macaque model warrants further
research into why engaging the complement system is capable
of eliciting potent sterilising protection in the context of anti-cell
responses and how this potent viral killing mechanism is so
effectively defeated in the context of anti-HIV gp160 proteins.
Overcoming this functional block to antibody mediated protec-
tion may prove to be an easier hurdle to overcome than the
issue of antibody specificity.
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